NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics Inc (NASDAQ:MRTX) announced its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($1.25) by $0.13. The biotechnology company earned $0.99 million during the quarter, compared to analyst estimates of $0.50 million. Mirati Therapeutics had a negative net margin of 2,698.66% and a negative return on equity of 48.60%. View Mirati Therapeutics' Earnings History.

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

16 brokers have issued 12-month price targets for Mirati Therapeutics' stock. Their forecasts range from $81.00 to $134.00. On average, they anticipate Mirati Therapeutics' stock price to reach $107.93 in the next year. This suggests a possible upside of 14.4% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

News stories about MRTX stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mirati Therapeutics earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the near term. View News Stories for Mirati Therapeutics.

Some companies that are related to Mirati Therapeutics include GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND) and ACADIA Pharmaceuticals (ACAD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Exelixis (EXEL), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Canopy Growth (CGC), Amarin (AMRN), Netflix (NFLX), NVIDIA (NVDA) and Tandem Diabetes Care (TNDM).

Mirati Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.12%), Perceptive Advisors LLC (8.12%), FMR LLC (5.11%), Janus Henderson Group PLC (4.96%), Sands Capital Management LLC (4.57%) and State Street Corp (3.13%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

MRTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Pictet Asset Management Ltd., Farallon Capital Management LLC, Schonfeld Strategic Advisors LLC, State Street Corp, Driehaus Capital Management LLC and Credit Suisse AG. Company insiders that have sold Mirati Therapeutics company stock in the last year include Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Jamie A Donadio, Michael G Grey and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Lord Abbett & CO. LLC, Eagle Asset Management Inc., Amundi Pioneer Asset Management Inc., UBS Asset Management Americas Inc., Sofinnova Investments Inc., Victory Capital Management Inc. and Victory Capital Management Inc.. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $94.38.

Mirati Therapeutics has a market capitalization of $3.72 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

The official website for Mirati Therapeutics is http://www.mirati.com/.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]